AGEN : Summary for Agenus Inc. - Yahoo Finance

U.S. Markets closed

Agenus Inc. (AGEN)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.10+0.15 (+3.80%)
At close: 4:00 PM EST
People also watch:
CTICARRYARIACRISEXEL
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close3.95
Open3.95
Bid3.60 x 1000
Ask4.29 x 300
Day's Range3.93 - 4.21
52 Week Range2.61 - 7.49
Volume1,066,719
Avg. Volume1,406,111
Market Cap357.23M
Beta2.89
PE Ratio (TTM)-3.04
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Agenus' INCAGN1876 in Phase I/II Study for Solid Tumors
    Zacks2 days ago

    Agenus' INCAGN1876 in Phase I/II Study for Solid Tumors

    Agenus (AGEN) announced that it has dosed the first patient in a phase I/II study on INCAGN1949 for the treatment of patients with solid tumors.

  • PR Newswire3 days ago

    Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-OX40 Checkpoint Antibody INCAGN1949 in Patients with Solid Tumors

    LEXINGTON, Mass., Nov. 30, 2016 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that the first patient has been dosed in a Phase 1/2 clinical trial of the anti-OX40 agonist antibody INCAGN1949. The trial is being conducted by, and in collaboration with, Incyte Corporation. "We are pleased with the progress of our fruitful alliance with Incyte and also anticipate advancing a number of Agenus programs outside of the Incyte collaboration, such as our PD-1 antagonist, AGEN2034, into clinical development in the coming months," said Garo H. Armen, Ph.D. Chairman and CEO of Agenus.

  • 3 Red Flags on Agenus Inc's Balance Sheet
    Motley Fool10 days ago

    3 Red Flags on Agenus Inc's Balance Sheet

    One of the clinical-stage biopharma's biggest risks is its own balance sheet. Here's why.